SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Givaudan S.A. (GVDNY) trades at a trailing P/E of 31.9, forward P/E of 29.2. Trailing earnings yield is 3.13%, forward earnings yield 3.42%. PEG 3.18.
Criteria proven by this page:
- VALUE (77/100, Pass) — analyst target implies upside (+49.2%).
- Forward P/E 29.2 (down from trailing 31.9) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 3.18 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 3.13% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 3.42% as earnings recover.
- Analyst consensus target $110.00 (+49.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 71/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
77/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GVDNY
Valuation Multiples
P/E (TTM)31.9
Forward P/E29.2
PEG Ratio3.18
Forward PEG3.18
P/B Ratio0.00
P/S Ratio4.57
EV/EBITDA0.0
Per Share Data
EPS (TTM)$2.31
Forward EPS (Est.)$2.52
Book Value / Share$0.00
Revenue / Share$16.12
FCF / Share$0.00
Yields & Fair Value
Earnings Yield3.13%
Forward Earnings Yield3.42%
Dividend Yield0.00%
Analyst Target$110.00 (+49.2%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.39 |
$4.66B |
$644M |
13.8% |
| 2017 |
$1.55 |
$5.05B |
$720M |
14.3% |
| 2018 |
$1.43 |
$5.53B |
$663M |
12% |
| 2019 |
$1.51 |
$6.2B |
$702M |
11.3% |
| 2020 |
$1.60 |
$6.32B |
$743M |
11.8% |
| 2021 |
$1.77 |
$6.68B |
$821M |
12.3% |
| 2022 |
$1.85 |
$7.12B |
$856M |
12% |
| 2023 |
$1.93 |
$6.92B |
$893M |
12.9% |
| 2024 |
$2.35 |
$7.41B |
$1.09B |
14.7% |
| 2025 |
$2.31 |
$7.47B |
$1.07B |
14.3% |
